Home World News FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy... World News FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC By Ogkologos - July 29, 2026 176 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper May 21, 2019 With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... February 9, 2022 Our 10 top tips to help you talk about cancer April 24, 2023 Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... July 13, 2022 Load more HOT NEWS Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... How to Maintain Your Sexual Health During and After Lung Cancer ¿Qué es la escasez de medicamentos y cómo puede afectar a... ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21...
